Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AAVCAGsCD59 in Advanced Dry AMD with Geographic Atrophy
NCT03144999Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2017
- Primary completion
- Dec 2017
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
Phase 1, open-label trial of JNJ-81201887 in geographic atrophy (GA) and age-related macular degeneration (AMD) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Number of participants experiencing ocular and systemic adverse events at 26 weeks. Started Mar 2017; status: completed.
02
Drugs
JNJ-81201887
03
Conditions
geographic atrophy (GA)age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT03144999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03144999.